Cancer Treatment News and Research

RSS
Mary's Place by the Sea - helping women with cancer

Mary's Place by the Sea - helping women with cancer

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Philips to highlight range of Magnetic Resonance solutions at 23rd ISMRM

Philips to highlight range of Magnetic Resonance solutions at 23rd ISMRM

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

People with common form of lung cancer can benefit from nivolumab drug

People with common form of lung cancer can benefit from nivolumab drug

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Research shows HEOR data can be used to better determine value-based reimbursement strategies

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

Study shows increased sexual dysfunction in women following gynecologic cancer treatment

Study shows increased sexual dysfunction in women following gynecologic cancer treatment

Myriad Genetics to highlight new clinical studies on myRisk Hereditary Cancer test at ASCO 2015

Myriad Genetics to highlight new clinical studies on myRisk Hereditary Cancer test at ASCO 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.